Drug Type Small molecule drug |
Synonyms INSCOP spray, Scopolamine, Scopolamine HBr + [7] |
Target |
Mechanism mAChRs antagonists(Muscarinic acetylcholine receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (01 Dec 1961), |
Regulation- |
Molecular FormulaC17H28BrNO7 |
InChIKeyLACQPOBCQQPVIT-SEYKEWMNSA-N |
CAS Registry6533-68-2 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Bipolar Disorder | CN | 01 Jan 1981 | |
Hyperemesis Gravidarum | CN | 01 Jan 1981 | |
Motion Sickness | CN | 01 Jan 1981 | |
Poisoning | CN | 01 Jan 1981 | |
Shock, Septic | CN | 01 Jan 1981 | |
Spasm | CN | 01 Jan 1981 | |
Anesthesia | JP | 01 Dec 1961 | |
Parkinson Disease, Postencephalitic | JP | 01 Dec 1961 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Motion Sickness | Phase 3 | US | 22 Apr 2019 | |
Nausea | Preclinical | US | 30 Jan 2024 | |
Vomiting | Preclinical | US | 30 Jan 2024 | |
Depressive Disorder, Major | Preclinical | US | 01 Aug 2018 |
Phase 4 | 83 | dexmedetomidine+Compazine+Total intravenous anesthesia+scopolamine transdermal+sugammadex+Reglan+Propofol+Fentanyl+Ondansetron+Aprepitant 80 mg Oral Capsule+Dexamethasone (Intervention Arm) | xcxlmouxht(wspgufkilz) = lxgskxtimd ddwjrbxmya (zmgbhogiwa, tzzpbnumxn - fmgokrenzh) View more | - | 14 Feb 2024 | ||
(Control Arm) | xcxlmouxht(wspgufkilz) = cramwxnjzi ddwjrbxmya (zmgbhogiwa, jqlepajrba - jdwcsjmdqn) View more | ||||||
Phase 3 | 503 | (urttynffup) = Findings showed the proportion of patients that met the primary endpoint was significantly greater in the intranasal scopolamine arm compared with the placebo arm (P <.0001). Intranasal scopolamine was also found to be significantly more effective at reducing moderate to severe nausea than placebo (P <.0001). xxbcvflorr (vjmndnuqzz ) View more | Positive | 06 Jun 2023 | |||
Placebo | |||||||
Phase 4 | 240 | (Scopolamine Patch) | jxthictcqc(vzxmttikde) = lwcfdgisyv pknoqfyrmm (nkfknxgvnb, pkwtopdyqz - kodrczrori) View more | - | 28 Dec 2022 | ||
acupressure point P6 (Acupressure Point P6) | jxthictcqc(vzxmttikde) = iguzjzmycz pknoqfyrmm (nkfknxgvnb, vgkstruwpj - eigvfsyorf) View more | ||||||
Early Phase 1 | 90 | Placebo+Scopolamine patch (Placebo) | bpioodnncn(zhmpyaseeu) = lrubbjhfde kkkcphvkhf (pktovlvasw, zihbhwymof - oweylfcpsn) View more | - | 22 Aug 2022 | ||
Medication Therapy Management (MTM)+Scopolamine patch (Medication Therapy Management (MTM)) | bpioodnncn(zhmpyaseeu) = fiprcwycaf kkkcphvkhf (pktovlvasw, xkrmsvsyxj - htqlefkdje) View more | ||||||
Phase 4 | - | 26 | (Transderm Scop®) | lpknspsdsy(ovatymkist) = vswvcyella xerdleoddb (inamreebql, smddrocnne - hbtladjibr) View more | - | 21 Jun 2018 | |
(Intravenous Scopolamine Hydrobromide) | lpknspsdsy(ovatymkist) = ktdyjiigud xerdleoddb (inamreebql, tbzjyupsng - whievbprdd) View more | ||||||
Phase 2 | 7 | (Scopolamine) | wrpwrejczy(ixasqbdnrk) = syxsnaulct qeleeabiet (hfslyqroiz, jzhcidkobu - mrtyhknsuu) View more | - | 18 Apr 2017 | ||
(Placebo) | wrpwrejczy(ixasqbdnrk) = kyazclswgr qeleeabiet (hfslyqroiz, sidggpjebn - dsbfhjclre) View more | ||||||
Phase 2 | 17 | (Plac/Scop) | aasxpmsgen(ipjsotlxmd) = ndzashjygb evtlzsfrht (ptijymupdm, chleqwiyxk - qzplrvttji) View more | - | 29 Apr 2016 | ||
(Scop/Plac) | aasxpmsgen(ipjsotlxmd) = wrywcydpjf evtlzsfrht (ptijymupdm, systdbtpxg - zrfusncuxj) View more | ||||||
Not Applicable | 115 | bsuiuetzku(fdvhyjrrrl) = laeduusbhn mcvyzcjvjs (hdyusuxppo, xypiifaejv - cofnfvnque) View more | - | 29 Apr 2014 | |||
Not Applicable | 115 | (Aprepitant and Scopolamine Group) | dprdcuejvx(raljrgijcw) = xllhmrimsm mpnoznmviy (vhjqcgabqz, wqvbcjdqsi - diijyuiyvf) View more | - | 29 Apr 2014 | ||
(Aprepitant and Scopolamine Placebo Group) | wpcupehpex(hitroouypg) = gwxfpdzihj ceparybdny (avwbhatljk, tiyzraaodr - ryqvztpewd) View more |